Skip to main content

Advertisement

SpringerLink
Log in

Updates in Pediatric Cholestasis

  • Pediatric Gastroenterology (SA Saeed and E Mezoff, Section Editors)
  • Published:
Current Treatment Options in Pediatrics Aims and scope Submit manuscript

Abstract

Purpose of Review

Cholestasis is a common disorder in pediatric hepatology with a wide variety of causative etiologies. The presentation of jaundice can be frightening. Several therapies are time sensitive, and a prompt diagnosis may improve outcomes. The purpose of this paper will be to review the etiology, diagnosis, and complications of cholestasis in children and to discuss current recommendations for the management of pediatric cholestasis.

Recent Findings

Medical management of pediatric cholestasis has traditionally been supportive, with care centered on nutrition, growth, and treatment of pruritus. The approval of new therapies for pruritus has changed the approach to disease management in certain diseases. Referral to a transplant center when there is advanced disease or significantly impaired quality of life remains important.

Summary

There are many facets to pediatric cholestasis and attention to ameliorating the complications commonly associated with them requires subspecialized care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Harpavat S, et al. Diagnostic yield of newborn screening for biliary atresia using direct or conjugated bilirubin measurements. JAMA. 2020;323(12):1141–50.

    Article  CAS  Google Scholar 

  2. Gotze T, et al. Neonatal cholestasis - differential diagnoses, current diagnostic procedures, and treatment. Front Pediatr. 2015;3:43.

    Google Scholar 

  3. Hoofnagle JH. Chapter 40 - LiverTox: A website on drug-induced liver injury. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease (third edition). Boston: Academic Press; 2013. p. 725–32.

    Chapter  Google Scholar 

  4. Ushigome Y, et al. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68(5):721–8.

    Article  Google Scholar 

  5. Kardaun SH, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80.

    Article  CAS  Google Scholar 

  6. Gura KM, et al. Fish oil emulsion reduces liver injury and liver transplantation in children with intestinal failure-associated liver disease: a multicenter integrated study. J Pediatr. 2021;230:46-54 e2.

    Article  CAS  Google Scholar 

  7. Heubi JE, Bove KE, Setchell KDR. Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and Zellweger spectrum disorders. J Pediatr Gastroenterol Nutr. 2017;65(3):321–6.

    Article  CAS  Google Scholar 

  8. Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, Waisbren SE, Gucsavas-Calikoglu M, Wasserstein MP, Coakley K, Scott CR. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12):1380–95. https://doi.org/10.1038/gim.2017.101.

    Article  Google Scholar 

  9. Welling L, et al. International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up. J Inherit Metab Dis. 2017;40(2):171–6.

    Article  Google Scholar 

  10. Taylor SA, et al. The effects of gestational alloimmune liver disease on fetal and infant morbidity and mortality. J Pediatr. 2018;196:123-128 e1.

    Article  Google Scholar 

  11. Kriegermeier A, Green R. Pediatric cholestatic liver disease: review of bile acid metabolism and discussion of current and emerging therapies. Front Med (Lausanne). 2020;7:149.

    Article  Google Scholar 

  12. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36(3):525–31.

    Article  CAS  Google Scholar 

  13. Gregorio GV, et al. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Child. 1993;69(1):141–3.

    Article  CAS  Google Scholar 

  14. Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid system. JAMA. 1992;268(23):3359–62.

    Article  CAS  Google Scholar 

  15. Thornton JR, Losowsky MS. Plasma leucine enkephalin is increased in liver disease. Gut. 1989;30(10):1392–5.

    Article  CAS  Google Scholar 

  16. Thebaut A, et al. Sertraline as an additional treatment for cholestatic pruritus in children. J Pediatr Gastroenterol Nutr. 2017;64(3):431–5.

    Article  CAS  Google Scholar 

  17. Mayo MJ, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45(3):666–74.

    Article  CAS  Google Scholar 

  18. Baumann U, et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. Clin Res Hepatol Gastroenterol. 2021;45(5): 101751.

    Article  CAS  Google Scholar 

  19. Gonzales E, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581–92.

    Article  CAS  Google Scholar 

  20. Sundaram SS, et al. Health related quality of life in patients with biliary atresia surviving with their native liver. J Pediatr. 2013;163(4):1052-7 e2.

    Article  Google Scholar 

  21. Squires JE, et al. Neurodevelopmental outcomes in preschool and school aged children with biliary atresia and their native liver. J Pediatr Gastroenterol Nutr. 2020;70(1):79–86.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Feinberg Medical School, Northwestern University, Chicago, IL, USA

    Alyssa Kriegermeier MD

  2. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA

    Saeed Mohammad MD

  3. Monroe Carell Jr Childrens Hospital at Vanderbilt, 2200 Childrens Way, DOT 10th Floor, Nashville, TN, 37232, USA

    Saeed Mohammad MD

Authors
  1. Alyssa Kriegermeier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeed Mohammad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saeed Mohammad MD.

Ethics declarations

Conflict of Interest

SM has been on advisory boards for Albireo and Mirum. AK has no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Gastroenterology

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kriegermeier, A., Mohammad, S. Updates in Pediatric Cholestasis. Curr Treat Options Peds 8, 346–353 (2022). https://doi.org/10.1007/s40746-022-00257-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40746-022-00257-8

Keywords

Search

Navigation